The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR study

被引：0
|
作者：
Muhlestein, JB
Thomas, H
Jensen, JR
Horne, BD
Lanman, RB
Lavasani, F
Wolfert, RL
Pearson, RR
Anderson, JL
机构：
[1] LDS Hosp, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2006年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：377A / 377A
页数：1
相关论文
共 50 条
  • [1] The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia - The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study
    Muhlestein, Joseph B.
    May, Heidi T.
    Jensen, Jonathan R.
    Horne, Benjamin D.
    Lanman, Richard B.
    Lavasani, Farangis
    Wolfert, Robert L.
    Pearson, Robert R.
    Yannicelli, H. Daniel
    Anderson, Jeffrey L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (02) : 396 - 401
  • [2] Combination statin and fibrate therapy improves lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia: The DIACOR study
    Thomas, H
    Jensen, JR
    Anderson, JL
    Lavasani, F
    Pearson, RR
    Horne, BD
    Muhlestein, JB
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 355A - 355A
  • [3] Combination treatment of diabetic dyslipidemia with statin and fibrate
    Zeman, M
    Zák, A
    Tvrzická, E
    Vareka, T
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S161 - S161
  • [4] Triple-therapy with a statin, fibrate and ezetimibe safely allows more diabetic patients with mixed dyslipidemias to reach NCEP guidelines:: An analysis of the DIACOR study
    Pearson, RR
    Thomas, H
    Jensen, JR
    Horne, BD
    Lappé, DL
    Anderson, JL
    Muhlestein, JB
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 316A - 316A
  • [5] Pharmacoepidemiology Safety Study of Statin, Fibrate, or Statin-Fibrate Combination Therapy
    Enger, Cheryl
    Gately, Robert
    Niemcryk, Steve J.
    Ming, Eileen E.
    McAfee, Andrew T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S268 - S268
  • [6] Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysis
    Choi, Hye Duck
    Shin, Wan Gyoon
    Lee, Ju-Yeun
    Kang, Byoung Cheol
    VASCULAR PHARMACOLOGY, 2015, 65-66 : 23 - 30
  • [7] Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy
    Fazio, Sergio
    CLINICAL THERAPEUTICS, 2008, 30 (02) : 294 - 306
  • [8] Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
    Alagona, Peter, Jr.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 351 - 362
  • [9] Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus
    Reyes-Soffer, Gissette
    Rondon-Clavo, Carlos
    Ginsberg, Henry N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (09) : 1429 - 1438
  • [10] Statin therapy among schizophrenia patients with dyslipidemia
    Wampers, M
    De Hert, M
    Hanssens, L
    Van Eck, D
    Scheen, A
    Peuskens, J
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 141 - 141
12345